Article info

NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case–control study

Authors

  • Gwen M C Masclee Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The NetherlandsDepartment of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Preciosa M Coloma Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Manon C W Spaander Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Ernst J Kuipers Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Miriam C J M Sturkenboom Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The NetherlandsDepartment of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands PubMed articlesGoogle scholar articles
  1. Correspondence to Gwen M C Masclee; g.masclee{at}erasmusmc.nl
View Full Text

Citation

Masclee GMC, Coloma PM, Spaander MCW, et al
NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case–control study

Publication history

  • Received September 15, 2014
  • Revised November 9, 2014
  • Accepted January 7, 2015
  • First published January 29, 2015.
Online issue publication 
October 25, 2017
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.